$PBLA
Panbela Therapeutics, Inc.

2019 Q3 Form 10-Q Financial Statement

#000143774919016431 Filed on August 13, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2019 Q2 2018 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $620.0K $580.0K $330.0K
YoY Change 31.91% -10.77% -71.79%
% of Gross Profit
Research & Development $720.0K $508.0K $310.0K
YoY Change 60.0% 14.93% -51.56%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $720.0K $508.0K $640.0K
YoY Change 60.0% 14.93% -64.64%
Operating Profit -$1.342M -$1.088M
YoY Change 46.35% -0.73%
Interest Expense $3.000K $1.152M -$50.00K
YoY Change 0.0% -10.56% -89.36%
% of Operating Profit
Other Income/Expense, Net -$222.0K -$1.253M -$140.0K
YoY Change 252.38% -14.65% -450.0%
Pretax Income -$1.564M -$2.341M -$830.0K
YoY Change 59.59% -8.7% -62.95%
Income Tax -$190.0K -$70.00K -$90.00K
% Of Pretax Income
Net Earnings -$1.374M -$2.271M -$740.0K
YoY Change 48.54% -8.69% -65.74%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$228.0K -$447.7K -$145.7K
COMMON SHARES
Basic Shares Outstanding 5.722M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q3 2019 Q2 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.380M $720.0K $1.410M
YoY Change 1308.33% -20.88% 840.0%
Cash & Equivalents $3.377M $721.0K $1.405M
Short-Term Investments
Other Short-Term Assets $120.0K $90.00K $110.0K
YoY Change 0.0% 0.0% -45.0%
Inventory
Prepaid Expenses $119.0K $93.00K $110.0K
Receivables
Other Receivables
Total Short-Term Assets $3.771M $1.288M $1.847M
YoY Change 322.76% -13.9% 140.81%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $49.00K $51.00K $51.00K
YoY Change -7.55% -7.27%
Total Long-Term Assets $49.00K $51.00K $51.00K
YoY Change -7.55% -7.27%
TOTAL ASSETS
Total Short-Term Assets $3.771M $1.288M $1.847M
Total Long-Term Assets $49.00K $51.00K $51.00K
Total Assets $3.820M $1.339M $1.898M
YoY Change 304.23% -13.67% 147.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $261.0K $289.0K $1.064M
YoY Change -74.34% -69.12% -11.04%
Accrued Expenses $223.0K $192.0K $216.0K
YoY Change 59.29% 38.13% -82.78%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $200.0K $232.0K $286.0K
YoY Change -33.33% -22.67% 1942.86%
Total Short-Term Liabilities $689.0K $714.0K $1.630M
YoY Change -53.67% -50.45% -60.91%
LONG-TERM LIABILITIES
Long-Term Debt $740.0K $740.0K
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $740.0K $740.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $689.0K $714.0K $1.630M
Total Long-Term Liabilities $740.0K $740.0K
Total Liabilities $1.431M $1.456M $1.630M
YoY Change -3.77% 1.04% -63.42%
SHAREHOLDERS EQUITY
Retained Earnings -$40.28M -$38.91M -$35.06M
YoY Change 17.38% 16.52% 20.26%
Common Stock $7.000K $6.000K $5.000K
YoY Change 40.0% 20.0% 25.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.389M -$117.0K $268.0K
YoY Change
Total Liabilities & Shareholders Equity $3.820M $1.339M $1.898M
YoY Change 304.23% -13.67% 147.46%

Cashflow Statement

Concept 2019 Q3 2019 Q2 2018 Q4
OPERATING ACTIVITIES
Net Income -$1.374M -$2.271M -$740.0K
YoY Change 48.54% -8.69% -65.74%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$460.0K -$630.0K -$160.0K
YoY Change -28.12% -37.0% -79.75%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.120M -30.00K 1.330M
YoY Change -10500.0% -104.11%
NET CHANGE
Cash From Operating Activities -460.0K -630.0K -160.0K
Cash From Investing Activities
Cash From Financing Activities 3.120M -30.00K 1.330M
Net Change In Cash 2.660M -660.0K 1.170M
YoY Change -497.01% 144.44% -248.1%
FREE CASH FLOW
Cash From Operating Activities -$460.0K -$630.0K -$160.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Shell Company
EntityShellCompany
false
dei Document Period End Date
DocumentPeriodEndDate
2019-06-30
CY2019Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5722099
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Security12b Title
Security12bTitle
Common Stock
snbp Common Stock Converted Into Convertible Notes Payable Value
CommonStockConvertedIntoConvertibleNotesPayableValue
25000
snbp Common Stock Converted Into Convertible Notes Payable Value
CommonStockConvertedIntoConvertibleNotesPayableValue
CY2019Q1 snbp Common Stock Converted Into Convertible Notes Payable Value
CommonStockConvertedIntoConvertibleNotesPayableValue
25000
snbp Debt Conversion Conversion Of Promissory Notes And Accrued Interest Into Common Stock
DebtConversionConversionOfPromissoryNotesAndAccruedInterestIntoCommonStock
snbp Debt Conversion Conversion Of Promissory Notes And Accrued Interest Into Common Stock
DebtConversionConversionOfPromissoryNotesAndAccruedInterestIntoCommonStock
2908000
snbp Debt Conversion Conversion Of Promissory Notes And Accrued Interest Into Common Stock And Warrants
DebtConversionConversionOfPromissoryNotesAndAccruedInterestIntoCommonStockAndWarrants
2281000
snbp Debt Conversion Conversion Of Promissory Notes And Accrued Interest Into Common Stock And Warrants
DebtConversionConversionOfPromissoryNotesAndAccruedInterestIntoCommonStockAndWarrants
350000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
Sun BioPharma, Inc.
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Central Index Key
EntityCentralIndexKey
0001029125
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Trading Symbol
TradingSymbol
snbp
CY2018Q4 us-gaap Assets Current
AssetsCurrent
1847000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
721000
CY2018Q2 snbp Grant Income Nonoperating
GrantIncomeNonoperating
12000
snbp Grant Income Nonoperating
GrantIncomeNonoperating
CY2019Q2 snbp Grant Income Nonoperating
GrantIncomeNonoperating
snbp Grant Income Nonoperating
GrantIncomeNonoperating
22000
snbp Intrinsic Value Of Convertible Debt With Conversion Feature
IntrinsicValueOfConvertibleDebtWithConversionFeature
353000
snbp Intrinsic Value Of Convertible Debt With Conversion Feature
IntrinsicValueOfConvertibleDebtWithConversionFeature
121000
snbp Noncash Interest Expense
NoncashInterestExpense
102000
snbp Noncash Interest Expense
NoncashInterestExpense
43000
snbp Sharebased Compensation Arrangement By Sharebased Payment Award Number Of Shares Available For Grant Grants In Period
SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod
540800
snbp Stock Options Granted In Exchange For Release From Contingent Payment Obligations
StockOptionsGrantedInExchangeForReleaseFromContingentPaymentObligations
snbp Stock Options Granted In Exchange For Release From Contingent Payment Obligations
StockOptionsGrantedInExchangeForReleaseFromContingentPaymentObligations
1094000
snbp Unsecured Promissory Note Issued In Exchange For Vendor Accounts Payable
UnsecuredPromissoryNoteIssuedInExchangeForVendorAccountsPayable
742000
snbp Unsecured Promissory Note Issued In Exchange For Vendor Accounts Payable
UnsecuredPromissoryNoteIssuedInExchangeForVendorAccountsPayable
CY2019Q2 snbp Working Capital
WorkingCapital
600000
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
289000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1064000
CY2019Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
192000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
212000
CY2019Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
300000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
283000
CY2019Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
38487000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
35038000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
121000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
353000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1792000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
358000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
412000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
419000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
419000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
422000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2150000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2061000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1687000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
12000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
9000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4061688
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2406161
CY2019Q2 us-gaap Assets
Assets
1339000
CY2018Q4 us-gaap Assets
Assets
1898000
CY2019Q2 us-gaap Assets Current
AssetsCurrent
1288000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1405000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
152000
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
905000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-684000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
753000
CY2019Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2509477
CY2019Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4273837
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5722099
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5077483
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5722099
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5077483
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
6000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2222000
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2384000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3835000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4071000
CY2019Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
CY2018Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
64000
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.45
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.76
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-3000
CY2019Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
600000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
580000
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
654000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
883000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1312000
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2341000
CY2018Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2564000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3993000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-4348000
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-70000
CY2018Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-79000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-141000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-108000
CY2019Q2 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
474000
CY2018Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
332000
CY2019Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
742000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-12000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-67000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-20000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-20000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
144000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
106000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-17000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-53000
CY2019Q2 us-gaap Interest Expense
InterestExpense
1152000
CY2018Q2 us-gaap Interest Expense
InterestExpense
1288000
us-gaap Interest Expense
InterestExpense
2184000
us-gaap Interest Expense
InterestExpense
1761000
us-gaap Interest Paid Net
InterestPaidNet
8000
us-gaap Interest Paid Net
InterestPaidNet
22000
CY2019Q2 us-gaap Interest Payable Current
InterestPayableCurrent
1000
CY2018Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
286000
us-gaap Nature Of Operations
NatureOfOperations
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div> </div></div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Risks and Uncertainties</div></div> </td> </tr> </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (&#x201c;FDA&#x201d;) in the United States, the Therapeutic Goods Administration in Australia, the European Medicines Agency in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>take many years, and is normally expected to involve substantial expenditures.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We have incurred losses of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$38.9</div> million since our inception in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011.</div> For the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019, </div>we incurred a net loss of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.9</div> million, which includes the amortization of discount on debt of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.1</div> million. We also incurred negative cash flows from operating activities of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.4</div> million during this period. During this same period, we raised <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.8</div> million from the sale of convertible promissory notes and warrants to purchase common stock, as discussed in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div> titled &#x201c;Liquidity and Business Plan&#x201d;. These notes, sold in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2019, </div>and notes sold in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2018 </div>converted into common stock on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019. </div>As we continue to pursue development activities and seek commercialization of our initial product candidate, SBP-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">101,</div> we expect to incur substantial losses, which are likely to generate negative net cash flows from operating activities. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019, </div>we had cash of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.7</div> million, working capital (current assets less current liabilities) of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.6</div> million and stockholders&#x2019; deficit of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.1</div> million. The Company&#x2019;s principal sources of cash have historically included the issuance of convertible debt and equity securities.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The accompanying condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The condensed<div style="display: inline; font-weight: bold;"> </div>consolidated financial statements do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include any adjustments relating to the recoverability or classification of assets or the amounts of liabilities that might result from the outcome of these uncertainties. Our current independent registered public accounting firm included a paragraph emphasizing this going concern uncertainty in their audit report regarding our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> financial statements dated <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 22, 2019. </div>Our ability to continue as a going concern, realize the carrying value of our assets and discharge our liabilities in the ordinary course of business is dependent upon a number of factors, including our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our SBP-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">101</div> product candidate in the United States, Australia, the European Union or other markets and ultimately our ability to market and sell our SBP-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">101</div> product candidate. These factors, among others, raise substantial doubt about our ability to continue operations as a going concern. See Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div> titled &#x201c;Liquidity and Business Plan.&#x201d;</div></div>
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
730000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2341000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1414000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1585000
us-gaap Net Income Loss
NetIncomeLoss
-38900000
us-gaap Net Income Loss
NetIncomeLoss
-3852000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-2271000
CY2018Q4 us-gaap Interest Payable Current
InterestPayableCurrent
4000
CY2019Q2 us-gaap Liabilities
Liabilities
1456000
CY2018Q4 us-gaap Liabilities
Liabilities
1630000
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1339000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1898000
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
714000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1630000
CY2019Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
232000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-2485000
us-gaap Net Income Loss
NetIncomeLoss
-4240000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1753000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-1581000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1253000
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1468000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2252000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2012000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1088000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1096000
us-gaap Operating Income Loss
OperatingIncomeLoss
-1741000
us-gaap Operating Income Loss
OperatingIncomeLoss
-2336000
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
51000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
51000
CY2019Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
49000
CY2018Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
101000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
17000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
169000
CY2018Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
69000
CY2019Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-32000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-101000
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-192000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-68000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-273000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
7000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
27000
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
25000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
508000
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
442000
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
55000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
93000
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
110000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
810000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
2341000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
800000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
858000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1024000
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-38910000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-35058000
us-gaap Share Based Compensation
ShareBasedCompensation
422000
us-gaap Share Based Compensation
ShareBasedCompensation
1056000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.72
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0225
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
212149
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
732149
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
20800
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
540800
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
169495
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
32195
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1032211
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1552211
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.90
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.75
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
15.10
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.95
CY2019Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1182536
CY2019Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1552211
CY2019Q2 us-gaap Share Price
SharePrice
2.95
CY2019Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y182D
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P7Y135D
CY2019Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
6.746
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y335D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
CY2018Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
3258000
CY2019Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
2281000
CY2018Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1261000
CY2018Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1080000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-117000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
268000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-3689000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
-2320000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
110000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-588000
CY2019Q2 us-gaap Unsecured Long Term Debt
UnsecuredLongTermDebt
742000
CY2018Q4 us-gaap Unsecured Long Term Debt
UnsecuredLongTermDebt
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of estimates</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates.</div></div></div>
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5070341
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4570601
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5071378
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4248603

Files In Submission

Name View Source Status
0001437749-19-016431-index-headers.html Edgar Link pending
0001437749-19-016431-index.html Edgar Link pending
0001437749-19-016431.txt Edgar Link pending
0001437749-19-016431-xbrl.zip Edgar Link pending
ex_152976.htm Edgar Link pending
ex_152977.htm Edgar Link pending
ex_152978.htm Edgar Link pending
ex_152987.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snbp-20190630.xml Edgar Link completed
snbp-20190630.xsd Edgar Link pending
snbp-20190630_cal.xml Edgar Link unprocessable
snbp-20190630_def.xml Edgar Link unprocessable
snbp-20190630_lab.xml Edgar Link unprocessable
snbp-20190630_pre.xml Edgar Link unprocessable
snbp20190630_10q.htm Edgar Link pending